- Bristol-Myers Squibb has agreed to acquire Celgene, the drugmakers announced Thursday in a deal valued at $US74 billion.
- The deal will pay Celgene shareholders one BMS share and $US50 cash for each Celgene share they own.
- The deal combines a massive pharmaceutical company with a biotech giant, both of which have a big presence in the development of cancer drugs.
- Watch Celgene and BMS trade in real time.
In the first big pharmaceutical deal of the year, the pharma giant Bristol-Myers Squibb has snapped up the biotech giant Celgene in a $US74 billion deal.
Celgene shareholders will get one BMS share and $US50 cash for each Celgene share they own, valuing the New Jersey-based Celgene at about $US102.43 a share, according to the companies. That’s about 54% more than Celgene’s closing price on Wednesday.
Including the debt that’s part of the deal, it’s the largest healthcare deal on record. That’s according to Refinitiv, a financial data company.
The deal combines two companies that have made a lot of investments in cancer drugs, but both have faced challenges to their stock price amid competition.
The New York-based Bristol-Myers has faced stiff competition from companies such as Merck in an area of cancer treatment known as cancer immunotherapy. Two BMS drugs, Opdivo and Yervoy, harness the body’s immune system to treat cancer.
“As a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation,” BMS CEO Giovanni Caforio said in a news release Thursday.
Celgene had a tough 2018, even after doing big-ticket deals like the $US9 billion acquisition of Juno Therapeutics and the $US7 billion purchase of Impact Biosciences. In 2018, Celgene’s stock fell about 40% and the company faces competition for its blockbuster cancer treatment, Revlimid.
BMS and Celgene said they were expecting near-term launches of new drugs to make up $US15 billion in revenue.
BMS also said it was expecting to realise $US2.5 billion in synergies by 2022. Synergies indicate areas where investment bankers or the firms involved in the deal have identified redundancies or opportunities to make the combined company leaner, thus saving on costs.
While synergies can also mean cutting redundancies in things like software and machinery, a large chunk of the savings typically comes from reduced employee headcounts.
- Read more:
- Bristol-Myers Squibb and Celgene said their huge merger has about $US2.5 billion in ‘synergies.’ That should make employees nervous.
- 10 surprises that could rock biotech stocks in 2019, from success in Alzheimer’s to a stumble in depression
- A tiny boutique landed a big role on the $US74 billion Bristol-Myers-Celgene deal
- Here’s why Bristol-Myers Squibb’s record-breaking $US74 billion biotech deal is facing investor backlash
Business Insider Emails & Alerts
Site highlights each day to your inbox.